We read the article ''Endocan-A Novel Inflammatory Indicator in Newly Diagnosed Patients With Hypertension: A Pilot Study'' by Balta et al. 1 They evaluated serum levels of endocan in newly diagnosed patients with untreated essential hypertension (HT). They concluded that endocan may be a surrogate endothelial dysfunction marker and may have a functional role in endothelium-dependent pathological disorders.
Atherosclerosis is the most frequent cause of death worldwide. Inflammation plays an important role in the pathogenesis of atherosclerosis. 2 Endothelial dysfunction is regarded as the initial lesion in the development of atherosclerosis. 3 Elevated levels of systemic inflammatory markers are associated with cardiovascular (CV) disease. 4 Endocan is a new candidate immunoinflammatory marker that may be associated with CV diseases and their clinical consequences. 5 Hypertension and endothelial dysfunction are associated although the underlying mechanisms are not completely defined. 4 It is possible that endothelial injury and dysfunction are caused by oxidative stress in the relationship between HT and endothelial dysfunction. Epidemiologic data support an association between different inflammatory markers and HT. 6 Furthermore, inhibiting endocan release by neutralizing endocan antibody enhanced survival rate. 7 Yilmaz et al also demonstrated that plasma endocan concentrations correlated positively with both markers of inflammation, and endocan levels were associated with allcause mortality and CV events in patients with chronic kidney disease. 5 Endocan was a strong predictor of overall and CV mortality in these patients. 5 Endocan may have potential as a useful long-term indicator of chronic renal allograft injury in renal transplant recipients, but further study is needed to verify these findings. 8 Tok and coworkers 9 reported that serum endocan concentrations decreased in patients with liver disease. In contrast to previous studies, they showed a negative correlation between endocan levels and inflammation stage of chronic hepatitis. Balta et al have previously shown that patients with Behçet disease (BD) had significantly higher serum levels of endocan. 10 Also, they have shown in patients with BD that serum endocan levels correlated positively with C-reactive protein and erythrocyte sedimentation rate and activity of the disease. 10 Serum levels of endocan were also higher in patients having BD with systemic involvement. 10 These authors have also shown that patients with psoriasis vulgaris had significantly higher serum levels of endocan. 11 Additionally, in patients with psoriasis, serum endocan levels correlated positively with CV risk and activity of disease. In addition, some medications may affect endocan levels. 11 Antihypertensive therapy (eg, valsartan and amlodipine) significantly lowered endocan levels in patients with newly diagnosed HT. 12 In this context, medication should be considered, when endocan is assessed. Although the authors 12 said that the main limitation of their study was the relatively small sample size and composed of newly diagnosed individuals with HT, small sample size may additionally not allow defining the inflammatory state in those patients with newly diagnosed HT. Moreover, duration from the onset to the actual diagnosis of HT could not be determined from current clinical and laboratory data.
In conclusion, endocan is a novel marker to assess endothelial dysfunction but without other inflammatory markers, endocan alone may not provide information to clinicians about the characteristics of inflammation in patients with HT. It would have been better if those factors were included in the article.
